What is Rocket Pharmaceuticals?
Rocket Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise specializing in the development of transformative gene therapies for rare and serious genetic conditions. The company leverages advanced research in genetic medicine to target diseases that currently lack viable treatment options. By maintaining a rigorous focus on scientific innovation, the organization bridges the gap between preclinical discovery and clinical-stage execution. Its market position is defined by a commitment to high-impact therapeutic development, operating within a collaborative framework that integrates cutting-edge laboratory research with strategic clinical development to bring novel solutions to patients globally.
How much funding has Rocket Pharmaceuticals raised?
Rocket Pharmaceuticals has raised a total of $68M across 3 funding rounds:
Private Equity
$16.4M
Private Equity
$25.1M
Share Placement
$26.4M
Private Equity (2015): $16.4M, investors not publicly disclosed
Private Equity (2017): $25.1M, investors not publicly disclosed
Share Placement (2021): $26.4M, investors not publicly disclosed
Key Investors in Rocket Pharmaceuticals
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Rocket Pharmaceuticals?
With the recent capital injection, Rocket Pharmaceuticals is well-positioned to scale its clinical development programs and expand its research infrastructure. The strategic focus will likely shift toward accelerating the progression of its lead candidates through late-stage clinical trials and enhancing its manufacturing capabilities to support potential commercialization. As the company navigates the complexities of the gene therapy landscape, this influx of financing provides the necessary runway to navigate regulatory milestones and deepen its pipeline of genetic medicine, ultimately aiming to redefine the standard of care for patients suffering from rare genetic disorders.
See full Rocket Pharmaceuticals company page
